Ann: Presentation of RP11 Clinical Trial Data at APVRS 2024, page-2

This is a big day in the journey so far.

from the release,

A/ Prof. Fred Chen of the Lions Eye Institute will present data from PYC's

ongoing phase 1/2 studies of VP-001 in patients with RP11 at the Asia

Highlights of A/Prof. Chen's presentation include improved vision in patients who have

received VP-001 with both sensitivity of the retina to light and visual acuity improving over

time in VP-001 treated eyes (when compared to both baseline assessment and the

contralateral untreated eye). Retinal sensitivity as assessed by microperimetry and visual

acuity as assessed by Low Luminance Visual Acuity (LLVA) assessment are both potentially

pyc owns 06 2% af ve o0t with the ey nceures 14

PYC is currently preparing for the transition into a registrational trial for VP-001 in patients

with RP11 including engaging with the US FDA in 1H 2025.